ProPhase Labs, Inc. (PRPH) shares ended the last trading session 8.5% higher at $8.42. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Shyam Venkatesan reported a 5.48 percent ProPhase Labs stake in a filing dated October 16, 2026. The position covered 855,101 ...

A bankruptcy claim of USD 25.00 million shaped the latest ProPhase Labs update on October 13, 2026. ProPhase Labs reported a ...

(RTTNews) - ProPhase Labs, Inc. (PRPH), a next-generation biotech and consumer products company, Thursday announced two key initiatives to strengthen its financial position and generate significant ...

ProPhase Labs (NASDAQ:PRPH) stock rose +12% Tuesday premarket as it named Stu Hollenshead as Chief Operating Officer, marking a pivotal step in the company’s expansion into consumer-centered health ...

ProPhase Labs is a diversified biotech company with profitable existing product lines and plans for expansion. The company's subsidiary, Nebula Genomics, offers whole genome sequencing and plans to ...

Ted Karkus, Chairman & CEO, opened by emphasizing the critical importance of shareholder voting on the company's proxy, noting, "If you do not vote for our proxy, you are putting our company in harm's ...

ProPhase Labs Inc. has announced the formation of a Clinical Science Advisory Board to support the commercialization of its BE-Smart™ molecular test for esophageal disease, aimed at early detection ...

ProPhase Labs, a genomics testing firm and dietary supplement marketer, has signed an agreement with an Abu Dhabi-based artificial intelligence firm to expand its genomic testing capabilities.

ProPhase Labs has put a diagnostic-testing unit into bankruptcy, a move it has been planning as a way to collect on millions of dollars in accounts receivables from its days processing Covid-19 tests ...